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Non-infectious uveitis is a potentially sight threatening disease. Along the years, several 
therapeutic strategies have been proposed as a means to its treatment, including local 
and systemic steroids, immunosuppressives and more recently, biologic agents. The 
introduction of biologics can be defined as a new era: biologic therapies provide new 
options for patients with refractory and sight threatening inflammatory disorders. 
The availability of such novel treatment modalities has markedly improved the 
therapy of uveitis and considerably increased the possibility of long-term remissions. 
This article provides a review of current literature on biologic agents, such as tumor 
necrosis factor blockers, anti-interleukins and other related biologics, such as interferon 
alpha, for the treatment of uveitis. Several reports describe the efficacy of biologics 
in controlling a large number of refractory uveitides, suggesting a central role in 
managing ocular inflammatory diseases. However, there is still lack of randomized 
controlled trials to validate most of their applications. Biologics are promising 
drugs for the treatment of uveitis, showing a favorable safety and efficacy profile. 
On the other hand, lack of evidence from randomized controlled studies limits our 
understanding as to when commence treatment, which agent to choose, and how 
long to continue therapy. In addition, high cost and the potential for serious and 
unpredictable complications have very often limited their use in uveitis refractory 
to traditional immunosuppressive therapy.
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INTRODUCTION
Intraocular inflammation is one of the leading 
causes of visual impairment and can be 
divided into non-infectious and infectious 
uveitis. Treatment for the former category is 
characterized by two phases of acute stage 
and maintenance therapy. The acute stage 
can be successfully controlled with the use of 
pharmacologic agents such as corticosteroids 
but when this phase is controlled, reduction in 
steroid dose is mandatory. Long-term treatment 
with steroids entails a certain number of systemic 
and ocular side effects such as hypertension, 
diabetes, cataracts and glaucoma. In cases of 
steroid dependency and high disease activity, 
immunotherapy is often initiated, however 
the treating physician frequently balances 
side effects with the therapeutic response. An 
increased understanding of mechanisms that 
result in non-infectious uveitis has made it 
possible to consider other means to abrogate Biologics for Uveitis; Posarelli et al
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the ocular immune response. After the advent 
of molecular biology techniques in the early 90s, 
several immunosuppressive agents have been 
proposed for treatment of ocular inflammation. 
Biologics are highly specific molecules targeting 
soluble inflammatory mediators; these include 
recombinant antibodies to, or antagonists of, 
particular cytokines or cell-surface receptors, 
and recombinant cytokines (such as interferons).
Biologic agents are promising drugs 
targeting specific molecules involved in 
inflammatory processes (Table 1). Over the last 
few years there have been a large number of 
reports on the use of biologic therapies to treat 
uveitis.1 Studies on anti-tumor necrosis factor 
(TNF)-α therapies and recombinant interferon 
(IFN)-α dominate the uveitis literature, with 
a limited number of reports on monoclonal 
antibody therapies against interleukins (for 
example IL-2 and IL-1b) and the vascular 
endothelial growth factor (VEGF). Results 
regarding their efficacy in uveitis are very 
promising, but each agent shows potential 
adverse effects and furthermore, the uveitis 
literature is mostly composed of uncontrolled 
trials or case-series. Many questions still remain 
unanswered about biologics: when to begin 
therapy, which agent and dose to use, and 
when to discontinue treatment. Due to high 
cost and limited long-term experience with 
biologic therapies, they are reserved for uveitis 
refractory to traditional immunosuppressives. 
However, the efficacy of these agents may justify 
their use earlier in the therapeutic process, as 
in Behcet’s disease.2 
In the present review we will summarize 
the most relevant applications of biologics in 
uveitis.
ANTI-TUMOR NECROSIS FACTOR AlPhA 
ThERAPIES
TNF-α is a key cytokine involved in the 
pathogenesis of many inflammatory disorders, 
including non-infectious uveitis. TNF-α is 
generated and expressed by immune cells 
and binds to the corresponding TNF receptor 
(TNFR) family. This cytokine has affinity 
for two receptors, known as p55 or TNF-R1, 
and p75 or TNF-R23,4 leading to signal 
transduction and stimulation of inflammation 
in autoimmune reactions. TNF-α activates 
T-cells and macrophages, by increasing the 
expression of endothelial adhesion molecules 
and pro-inflammatory cytokines.3,5,6
TNF-α plays a key role in the pathogenesis 
of many inflammatory diseases; it has been 
detected in all tissues affected by active 
inflammation, such as the synovial fluid in 
patients with rheumatoid arthritis (RA) or 
psoriasis arthritis (PsA), the bowel mucosa in 
Crohn’s disease or ulcerative colitis, and the 
eye during acute uveitis.
Non-infectious intermediate, posterior, 
and panuveitis7,8 are antigen-specific CD4 
T-cell–mediated autoimmune diseases. In these 
Name/Commercial name Indications Technology Mechanism of action
Adalimumab/Humira rheumatoid arthritis, ankylosing spondylitis, 
psoriatic arthritis, psoriasis, Crohn’s disease
monoclonal antibody TNF antagonist
Infliximab/Remicade rheumatoid arthritis, ankylosing spondylitis, 
psoriatic arthritis, psoriasis, Crohn’s disease
monoclonal antibody TNF antagonist





Daclizumab/Zenapax prevention of renal transplant rejection monoclonal antibody Interleukin-2 
receptor binder
Abatacept/Orencia rheumatoid arthritis immunoglobulin CTLA-4 
fusion protein
T-cell deactivation
Rituximab/ MabThera CD20-positive non-Hodgkins lymphoma, 
chronic lymphocytic leukemia, rheumatoid 
arthritis
monoclonal antibody CD20 antigen binder
Alemtuzumab/
Campath-1H
B-cell chronic lymphocytic leukemia  
(B-CLL)
monoclonal antibody CD52 antigen binder
Table. 1 List of the most relevant biologic agents used in ophthalmology.Biologics for Uveitis; Posarelli et al
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conditions, TNF-α represents one of the most 
important amplifying factors in inflammatory 
reactions9-11; in case of uveitis, TNF-α is found 
at high concentrations both in the aqueous 
humor and in the serum12-16, similar to RA17.
Currently there are three anti-TNF-α agents 
available: etanercept (a recombinant fusion 
protein, combining two human p75 TNF-α 
receptors linked to the Fc domain of human 
IgG1)18, infliximab (a mouse–human chimeric 
monoclonal IgG1 antibody against TNF-α)19, and 
adalimumab (a fully humanized monoclonal 
IgG1 antibody against TNF-α). Infliximab and 
adalimumab bind effectively both to soluble and 
trans-membrane TNF-α. In contrast etanercept 
forms less stable bonds with the transmembrane 
form of TNF-α.20 
Unfortunately, data emerging from the 
literature on etanercept are contradictory. 
Although etanercept has been proven to be 
effective in uveitis associated with different 
systemic disorders21-24, both infliximab and 
adalimumab have shown better control of 
uveitis compared to etanercept in retrospective 
studies and questionnaire-based surveys25-29. 
In addition, etanercept seems to be associated 
with exacerbation of uveitis and “de novo” 
induction of uveitis.30
Infliximab, the first commercially available 
anti-TNF-α agent, has been shown to be effective 
treatment for both anterior and posterior 
uveitis2,25,27-29,31-39. Infliximab is administered 
intravenously, at a usual dose of 3-10 mg/
kg, but doses as high as 10-20 mg/kg have 
been reported with success and few side 
effects in a group of 17 children with chronic 
uveitis.36 Behcet’s disease related posterior 
uveitis, seems to respond rapidly to infliximab 
infusions (range: less than 7 days to 3 weeks), 
as confirmed by the open-label cohort study 
by Tugal-Tutkun et al34, while non-Behcet’s 
posterior uveitis responds more variably (range: 
6 days to 2 months)2. 
Summarizing recent reports on infliximab 
therapy in refractory posterior uveitis suggests 
that in 78-100% of cases, an initial response to 
therapy was achieved2,25,27,31-37; however, the 
effect is temporary and repeated infusions are 
necessary every 4-8 weeks to maintain remission.
The high percentage of response to 
infliximab is encouraging, as all patients in 
these studies previously failed to respond 
to traditional therapies. Despite increasing 
the dose and frequency of infusions, some 
patients suffer from relapses or infusion related 
allergic reactions; this may be explained by the 
development of antibodies against the murine 
component of the molecule. For this reason, many 
clinicians prescribe concomitant therapy with 
an antimetabolite or glucocorticoid. Moreover, 
it is still not clear whether infliximab should be 
infused at variable or regular intervals40,41, in 
order to reduce allergic reactions and optimize 
the long term outcome.
There are several serious adverse events 
related to infliximab therapy, including an 
increased risk of malignancies, tuberculosis, 
multiple sclerosis, and lupus-like reactions, 
therefore such therapy should be avoided 
in patients with a positive history of these 
conditions.
Suhler et al33 reported a greater incidence of 
adverse events than any other recent study with 
six out of 23 (26%) patients developing possible 
infliximab related adverse events requiring 
withdrawal of treatment. This study also 
examined visual fields and electroretinograms 
with no significant deterioration at 1-year of 
follow up.
Infliximab showed efficacy for treatment 
of refractory uveitis associated with juvenile 
onset rheumatological disease, even in cases 
where previous biologics had failed.42
Adalimumab, a recombinant IgG1 
monoclonal antibody targeting TNF-α, showed 
efficacy both as monotherapy and in combination 
with other disease-modifying anti-rheumatic 
drugs (DMARDs), with favorable safety and 
efficacy profile in inflammatory rheumo-
arthropaties of different etiologies. Adalimumab 
has been proven to be effective in adults for 
treatment of RA43, ankylosing spondylitis 
(AS)44 and PsA45 by reducing symptoms of joint 
involvement and by inhibiting the progression 
of structural damage, typical of these immune-
mediated diseases. Unlike infliximab and other 
biologic agents which have to be administered 
intravenously, adalimumab has the advantage Biologics for Uveitis; Posarelli et al
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of subcutaneous administration resulting in 
smoother drug levels over time, and convenient 
self-administration at home. The usual dose 
is 40mg at 2-week intervals. Adalimumab is 
produced by recombinant deoxyribonucleic acid 
(DNA) technology, called “phage display”, and 
is classified as a fully humanized antibody, even 
though its humanization is not total. Mushtaq 
et al46 described three patients with quiescent 
panuveitis associated with Behcet’s disease, 
who were successfully switched from infliximab 
to adalimumab. All three patients remained in 
remission after 11–24 months of adalimumab 
therapy and there were no serious adverse 
events. In childhood uveitis,47,48 adalimumab 
shows 80–88% reduction in inflammation, with 
many patients being able to reduce or stop 
concomitant corticosteroids and second line 
immunosuppressives. In these reports, with 
a total of 33 patients, there were no adverse 
reactions other than pain and burning at the 
injection sites. Unfortunately the anatomical site 
of uveitis was not described, but this may be 
presumed to be mainly anterior as the majority 
of children had juvenile idiopathic arthritis 
(JIA). The results of these studies suggest that 
adalimumab may be a reasonable alternative to 
infliximab in the treatment of uveitis, but no 
studies have yet compared these agents.49 Until 
now, adalimumab has mostly been given in 
cases of failure to respond to other anti-TNF-α 
agents, or because of convenient administration.
ANTI-INTERlEUKIN ThERAPIES
In the pathophysiology of posterior uveitis, 
some experimental models of autoimmune 
uveitis have implicated the role of interleukin 
(IL)-1 and IL-2. Daclizumab is a humanized 
monoclonal antibody against the IL-2 receptor 
(particularly the 55 kDa chain of the IL-2 
receptor complex known as the Tac or CD25 
subunit). Nussenblatt et al50 described the use of 
4-weekly intravenous infusions of daclizumab 
for treatment of 10 patients with severe sight 
threatening intermediate and posterior uveitis. 
Eight out of 10 patients showed good control of 
disease over a 12-month period with concomitant 
tapering of standard immunosuppressive 
therapy. Similar results were observed by 
Hernandez Garfella et al51 who described 
reduced inflammatory activity in 70% of patients 
treated with intravenous daclizumab for 2 years, 
affected by refractory uveitis. Recently an open 
label study reported that daclizumab was able 
to stabilize visual acuity in 67% of patients 
with non-infectious intermediate, posterior, 
or panuveitis, concomitant with reduction in 
other immunosuppressives52. In this series, no 
serious adverse events were reported.
IL-1 receptor antagonist (IL-1RA) is a 
naturally occurring inhibitor of IL-1. Anakinra 
is a recombinant human IL-1RA, administered 
at a daily dose of 100 mg subcutaneously in 
adults. A case report described successful 
treatment with anakinra for chronic infantile 
neurological cutaneous articular syndrome 
(CINCA)-associated uveitis, refractory to anti-
TNF therapy. This confirms the success observed 
in a preclinical experimental autoimmune uveitis 
model in mice.54 For such reasons, anakinra 
may be considered as an alternative biologic 
agent in patients with JIA-associated uveitis 
refractory to anti-TNF therapy.
INTERFERONS
Although not properly a biologic agent, 
particular attention should be paid to a very 
interesting and promising drug, which is 
playing an important role in the management 
of severe sight threatening uveitis: interferon 
alpha (IFN-α). IFN-α is a naturally occurring 
cytokine secreted in response to viral infections, 
primarily by plasmacytoid dendritic cells. In 
simple terms, IFN-α is proposed as the primary 
pathogenic cytokine in ‘systemic’ autoimmune 
diseases, whereas TNF-α is believed to be the 
more pathogenic cytokine in organ-specific 
autoimmune diseases. TNF-α and IFN-α cross 
regulate each other; TNF-α reduces IFN-α 
levels by inhibiting the number and function 
of plasmacytoid dendritic cells.55
Recent studies have revealed many 
similarities between TNF-α blockers and IFN-α 
therapies for uveitis. Both agents have a rapid 
effect on intraocular inflammation and achieve 
control of uveitis in a high percentage of patients Biologics for Uveitis; Posarelli et al
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that have failed to respond to traditional second-
line immunosuppressives. 
Recombinant human IFN-α2a and IFN-α2b 
have both been used to treat posterior uveitis 
successfully, with the majority of studies using 
IFN-α2a. IFN-α56 is given by subcutaneous 
injections, commonly starting with high 
dose daily injections (6 mU per day) with a 
subsequent taper to low dose intermittent 
injections (3 mU, two or three times per week). 
It is a standard procedure to discontinue 
second-line immunosuppressives prior to IFN-α 
therapy, and many ophthalmologists also taper 
corticosteroids to the lowest dose possible.
The major experience with the use of IFN-α 
therapy involves patients affected with Behçet’s 
disease with response rates of 83 to 92%, within 
2 to 4 weeks.57-59 Recently, several reports 
have also included patients with other causes 
of uveitis including, sympathetic ophthalmia, 
Vogt-Koyanagi-Harada disease, birdshot 
chorioretinopathy, intermediate uveitis, and 
idiopathic panuveitis57,61.
IFN-α therapy can usually be stopped after 
6-12 months of relapse-free status: 20-40% of 
patients remained quiescent 7 to 58 months 
after IFN-α treatment58,59.
IFN-α precipitates a flu-like syndrome 
during the first week of treatment in almost 100% 
of patients, and depression has been reported in 
4-7.5% of subjects.58,59,61 Neutropenia, alopecia, 
elevated liver enzymes, epilepsy and injection 
site ulcers are potentially severe sequelae, 
causing discontinuation of treatment. IFN-β 
has also been reported as a useful treatment 
for intermediate uveitis associated with 
multiple sclerosis, choroiditis and choroidal 
neovascularization in chronic recurrent inner 
choroidopathy.62,63
OThER BIOlOGIC AGENTS
There are other monoclonal antibodies that 
have been used in uveitis refractory to standard 
immunosuppressive therapies; alemtuzumab, 
also known as Campath-1H, is a humanized 
monoclonal antibody against the pan-
lymphocyte antigen CD52. It has been used for 
five consecutive days by intravenous infusion 
and seems to be an effective treatment, leading 
to long term remission as shown in a report 
published in 2000.64 However, Campath-1H 
causes significant lymphopenia for several 
weeks exposing the patient to a higher risk 
of infections.
Rituximab is a mouse–human chimeric 
monoclonal IgG1 antibody against CD20, 
expressed by B-cells. It has been reported as 
an effective treatment for scleritis associated 
with Sjogren’s syndrome65 and Wegener’s 
granulomatosis66. Evidence that rituximab is 
effective in conditions traditionally considered 
as predominantly T cell mediated autoimmune 
diseases, such as rheumatoid arthritis and 
Wegener’s granulomatosis, suggests that this 
drug may also play a role in treating refractory 
uveitis. Rituximab may represent rescue therapy 
for severe JIA-associated uveitis refractory to 
traditional immunosuppressives and TNF-α 
inhibitors.67
CONClUSION
There has been a great deal of hope since 
the medical literature witnessed reports on 
successful results with several biologic agents for 
treatment of refractory inflammatory disorders 
such as RA, JIA, seronegative arthropathies and 
inflammatory bowel disease. This enthusiasm 
has extended to ophthalmology as remarkable 
remissions have been observed in patients with 
ocular inflammation failing all other treatments, 
particularly in patients with Behçet’s disease. 
Patients with refractory uveitis, like those with 
systemic autoimmune diseases, may have much 
to gain from treatment with biologic agents. 
However, despite the theoretical rationale, lack 
of evidence from randomized controlled studies 
limits our understanding of when to commence 
therapy, which agent to choose and how long 
to continue treatment. In addition, high cost 
and potential side effects of biologic drugs 
have limited their use in uveitis refractory to 
traditional immunosuppression. Fortunately 
many biologic agents are licensed for several 
systemic conditions associated with uveitis, such 
as AS and JIA, and access to biologic therapy 
in such patients can be less problematic.Biologics for Uveitis; Posarelli et al
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Research networks should be established to 
conduct randomized controlled trials comparing 
the efficacy of various biologic therapies. The 
results of such trials would provide evidence-
based data for clinical decisions, regarding 
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